middle.news
How Will LTR Pharma’s Clinical Advances Offset a 140% Surge in Losses?
8:22am on Thursday 26th of February, 2026 AEDT
•
Healthcare
Read Story
How Will LTR Pharma’s Clinical Advances Offset a 140% Surge in Losses?
8:22am on Thursday 26th of February, 2026 AEDT
Key Points
30% revenue growth to $587,060 in H1 FY26
Loss before tax increased 140% to $5.76 million
Phase II clinical trial approvals and patient dosing commenced for SPONTAN
US launch preparations underway for ROXUS in H1 CY2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
LTR PHARMA (ASX:LTP)
OPEN ARTICLE